Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state

Journal of Molecular Biology

Volumn 307, Issue 2, 2001, Pages 577-586

  Gall, Anne Laure ^a   Ruff, Marc ^a   Kannan, Rama ^a   Cuniasse, Philippe ^b   Yiotakis, Athanasios ^c   Dive, Vincent ^b   Rio, Marie Christine ^a   Basset, Paul ^a   Moras, Dino ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b CEA SACLAY   (France)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Drug design; Matrix metalloproteinases; Phosphinic inhibitor; Stromelysin 3 (MMP 11); X ray crystallography

Indexed keywords

MATRIX METALLOPROTEINASE INHIBITOR; PHOSPHINIC ACID DERIVATIVE; STROMELYSIN 3;

ARTICLE; BREAST CANCER; CRYSTAL STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBSTRATE; PRIORITY JOURNAL; PROTEIN PURIFICATION; X RAY CRYSTALLOGRAPHY;

EID: 0035937253     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.2001.4493     Document Type: Article

References (49)

1. Proteases: Invasion and more
2. Cancer invasion and tissue remodeling: Cooperation of protease systems and cell types
3. Matrix metalloproteinases
4. Matrix metalloproteinases and metastasis
5. Clinical studies with matrix metalloproteinase inhibitors
6. Clinical potential of matrix metalloprotease inhibitors
7. Structural properties of matrix metalloproteinases
8. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas
9. The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase
10. Identification of structural determinants controlling human and mouse stromelysin-3 proteolytic activities
11. Furin-dependent intracellular activation of the human stromelysin-3 zymogen
12. Characterization of structural determinants and molecular mechanisms involved in pro-stromelysin-3 activation by 4-aminophenyl-mercuric acetate and furin-type convertases
13. Stromelysin-3 gene expression in human cancer: An overview
14. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma
15. Stromelysin 3: An independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression
16. Stromelysin-3: A paradigm for stroma-derived factors implicated in carcinoma progression
17. Stromelysin-3 expression promotes tumor take in nude mice
18. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy
19. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity
20. X-ray structure of gelatinase a catalytic domain complexed with a hydroxamate inhibitor
21. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors
22. Stromelysin-1: Three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme
23. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor
24. Matrilysin-inhibitor complexes: Common themes among metalloproteases
25. Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself
26. 1.56 Å structure of mature truncated human fibroblast collagenase
27. Understanding the P1′ specificity of the matrix metalloproteinases: Effect of S1′ pocket mutations in matrilysin and stromelysin-1
28. Membrane type-1 matrix metalloprotease and stromelysin-3 cleave more efficiently synthetic substrates containing unusual amino acids in their P1′ positions
29. Molecular recognition of protein-ligand complexes
30. On the size of the active site in proteases. I. Papain
31. Structure of astacin with a transition-state analogue inhibitor
32. 2 Angstrom X-ray structure of adamalysin II complexed with a peptide phosphonate inhibitor adopting a retro-binding mode
33. Crystal structure of the complex of carboxypeptidase A with a strongly bound phosphonate in a new crystalline form: Comparison with structures of other complexes
34. Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: A structure-activity study
35. 1-Aminoalkylphosphonous acids. Part 1. Isosteres of the protein aminoacids
36. Absolute configuration for peptidomimetic residues in bioactive peptides
37. Purification of active matrix metalloproteinase catalytic domains and its use for screening of specific stromelysin-3 inhibitors
38. Characterization of crystal content by ESI-MS and MALDI-MS
39. Processing of X-ray diffraction data collected in oscillation mode
40. AMoRe: An automated package for molecular replacement
41. New applications of simulated annealing in X-ray crystallography and solution NMR
42. Improved methods for binding protein models in electron density maps and the location of errors in these models
43. The free R value: A novel statistical quantity for assessing the accuracy of crystal structures
44. Procheck: A program to check the stereochemical quality of protein structures
45. SETOR: Hardware lighted three-dimensional solid model representations of macromolecules
46. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons
47. Comparative protein modelling by satisfaction of spatial restraints
48. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design
49. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1